Fortrea Holdings (FTRE) Hisse Özeti
Bir sözleşmeli araştırma kuruluşu olan Fortrea Holdings Inc. dünya çapındaki ilaç, biyoteknoloji ve tıbbi cihaz müşterilerine biyofarmasötik ürün ve tıbbi cihaz geliştirme çözümleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
FTRE Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeFortrea Holdings Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$12.18 |
| 52 Haftanın En Yüksek Seviyesi | US$18.67 |
| 52 Haftanın En Düşük Seviyesi | US$3.97 |
| Beta | 1.78 |
| 1 Aylık Değişim | 28.89% |
| 3 Aylık Değişim | -25.05% |
| 1 Yıllık Değişim | 105.40% |
| 3 Yıllık Değişim | n/a |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -59.53% |
Son Haberler & Güncellemeler
Recent updates
FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating
The analyst price target for Fortrea has been reset from about $22.59 to $16.00 as analysts factor in updated fair value assumptions, slightly lower revenue growth and profit margin inputs, and a lower future P/E multiple, while also incorporating recent Street research that adjusts targets across firms in response to evolving views on the company's fundamentals and guidance. Analyst Commentary Recent Street research on Fortrea shows a mix of trimmed price targets and selective upgrades, as analysts recalibrate their models around updated guidance and sector views.FTRE: Margin Recovery Under New Leadership And Conservative 2026 Guidance May Drive Re Rating
Analysts nudged their price target for Fortrea slightly higher to $22.59 from $22.46, citing a mix of higher assumed profit margins, a lower future P/E multiple, and varied recent Street calls that balance upgraded ratings with trimmed targets in the $12 to $22 range. Analyst Commentary Recent Street research on Fortrea shows a wide range of opinions, but the most optimistic voices point to improving execution, clearer profit potential, and room for the shares to rerate as fundamentals stabilize.FTRE: Margin Recovery And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update The analyst price target for Fortrea has been revised lower from about $25 to roughly $22.46. This reflects analysts balancing recent price target cuts from several banks with more constructive views that cite improving execution, better fundamentals, and a clearer path to margin recovery under new leadership.
FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside
The analyst price target for Fortrea Holdings has shifted lower by about $2 to align with a refreshed fair value estimate of $14.44, as analysts factor in a higher discount rate, more cautious revenue growth assumptions, and only modestly revised margin and P/E inputs, despite recent rating upgrades and mixed target resets across the Street. Analyst Commentary Street research on Fortrea paints a mixed picture, with several firms turning more constructive on execution and earnings power, while others temper expectations for share price upside through lower targets.FTRE: Execution Improvements And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update on Fortrea Holdings: Analyst Price Target Shift The updated analyst price target for Fortrea Holdings reflects a higher implied valuation in dollar terms. Analysts are citing improved execution under new leadership, a clearer path to margin recovery, and recent target increases from firms that now see better revenue trends, margin potential, and benefits from deleveraging.The Market Doesn't Like What It Sees From Fortrea Holdings Inc.'s (NASDAQ:FTRE) Revenues Yet As Shares Tumble 33%
Feb 12
FTRE: Execution And Margin Recovery Under New Leadership Will Drive Future Upside
Narrative Update: Fortrea Holdings Our updated analyst price target for Fortrea moves higher by about $3, with analysts pointing to improving execution under new leadership, early commercial traction, a clearer path to margin recovery, and more supportive biopharma demand as key reasons for their revised expectations. Analyst Commentary Recent Street research on Fortrea reflects a more constructive tone, with several bullish analysts lifting price targets and upgrading ratings as they reassess the company’s execution, growth prospects, and margin potential.FTRE: Execution Gains And Biopharma Cycle Tailwinds May Drive Re Rating
Narrative Update on Fortrea Holdings Analysts have lifted their blended price expectations for Fortrea by several dollars, with new targets in the low to mid $20s and up to $25, citing improving execution under new leadership, a clearer path to margin recovery, and better perceived performance as the biopharma cycle picks up. This is broadly consistent with only modest tweaks to our discount rate, revenue growth, margin and future P/E assumptions and no change to our $25.00 fair value estimate.FTRE: New Leadership And Margin Recovery Path May Drive Re Rating
Analysts have raised their blended price target on Fortrea Holdings to about $25 from roughly $13, reflecting updated assumptions for stronger revenue growth, slightly improved profit margins, and a higher future P/E multiple, alongside recent upgrades and target increases from several firms. Analyst Commentary Bullish analysts are becoming more constructive on Fortrea Holdings, with a series of upgrades and price target increases that highlight improving company execution and a more supportive setup for profitability and valuation.FTRE: Rapid Share Gains Will Be Tested By Leadership Execution Risks
Analysts have nudged their average price target on Fortrea Holdings higher, from $12.07 to $13.25, citing encouraging early progress under new leadership, a steady Q3 book-to-bill backdrop, and signs that contract research and healthcare utilization trends may be stabilizing into 2026. Analyst Commentary Recent research updates reflect a cautiously constructive stance on Fortrea, with incremental target price hikes tied to operational progress and a stabilizing industry backdrop.FTRE: Rapid Share Gains Will Face Test From Leadership Transition Execution
Analysts have raised their fair value estimate for Fortrea Holdings from $11.21 to $12.07 per share, citing a lower perceived discount rate, slightly stronger long term revenue growth assumptions, and improving demand signals reflected in multiple recent price target increases across the Street. Analyst Commentary Bullish analysts point to a constructive setup for Fortrea as recent price target increases cluster in a narrow range above the prior consensus, suggesting growing confidence that execution under new leadership can support a re-rating.Fortrea Holdings Inc. (NASDAQ:FTRE) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Dec 07FTRE: Rapid Share Price Increase Will Challenge Upside Amid Mixed Industry Trends
Analysts have raised their average price target for Fortrea Holdings. Recent targets have moved from approximately $7-11 previously to as high as $14, reflecting improving internal execution, stabilizing industry trends, and cautious optimism regarding future demand.Fortrea Holdings: Showing Real Signs Of Life
Nov 20FTRE: Bookings Stability And Leadership Transition Will Shape Outlook Into 2026
Fortrea Holdings' analyst price target has increased significantly from $9.53 to $11.21, as analysts cite a more promising outlook supported by steady bookings, sector stabilization, and improving market demand. Analyst Commentary Recent analyst research highlights both positive developments and ongoing uncertainties for Fortrea Holdings.FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
The analyst price target for Fortrea Holdings has been raised from $7 to a range between $9 and $10. Analysts cite stabilizing healthcare cost trends and improving contract research bookings as key factors for their more optimistic outlook.Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their price target for Fortrea Holdings from $8.30 to $9.44, citing sustained improvements in revenue growth, stabilizing cost trends, and recent industry signals that point to a bottoming in contract research organization demand. Analyst Commentary Recent analyst updates highlight a shifting outlook for Fortrea Holdings, with both optimistic and cautious perspectives emerging from the latest research notes.Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their fair value estimate for Fortrea Holdings from $7.89 to $8.30 per share. They cite recent improvements in industry bookings and biotech funding, despite continued mixed demand signals.Global Demographic Trends Will Spur Clinical Advances
The upward revision in Fortrea Holdings’ price target is primarily driven by a lower discount rate, signaling reduced perceived risk and supporting the increase in fair value from $7.44 to $7.89. What's in the News Fortrea Holdings raised its full-year 2025 revenue guidance to $2.6–$2.7 billion.Health Check: How Prudently Does Fortrea Holdings (NASDAQ:FTRE) Use Debt?
Aug 14Global Demographic Trends Will Spur Clinical Advances
Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.Why Fortrea Holdings Inc. (NASDAQ:FTRE) Could Be Worth Watching
Jun 21New Therapeutic Areas And AI Adoption Will Fuel Progress
Expanding into therapeutic areas and strengthening partnerships may increase revenue through diversified client engagement.Is There An Opportunity With Fortrea Holdings Inc.'s (NASDAQ:FTRE) 49% Undervaluation?
May 08Is Fortrea Holdings (NASDAQ:FTRE) Using Debt Sensibly?
Apr 08Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds
Mar 06Benign Growth For Fortrea Holdings Inc. (NASDAQ:FTRE) Underpins Stock's 38% Plummet
Mar 04We Think Fortrea Holdings (NASDAQ:FTRE) Has A Fair Chunk Of Debt
Dec 27Fortrea: Turning Around As The Activists Move In
Dec 26Fortrea: Some Green Shoots After A Dismal Period
Nov 28There Is A Reason Fortrea Holdings Inc.'s (NASDAQ:FTRE) Price Is Undemanding
Nov 21Would Fortrea Holdings (NASDAQ:FTRE) Be Better Off With Less Debt?
Aug 16Hissedar Getirileri
| FTRE | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | 14.9% | -0.6% | 0.9% |
| 1Y | 105.4% | 2.7% | 28.2% |
Getiri vs. Endüstri: FTRE geçen yıl % 2.7 oranında getiri sağlayan US Life Sciences sektörünü aştı.
Getiri vs Piyasa: FTRE geçen yıl % 28.2 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| FTRE volatility | |
|---|---|
| FTRE Average Weekly Movement | 11.2% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: FTRE hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: FTRE 'nin haftalık oynaklığı ( 11% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2023 | 14,086 | Anshul Thakral | www.fortrea.com |
Bir sözleşmeli araştırma kuruluşu olan Fortrea Holdings Inc. dünya çapındaki ilaç, biyoteknoloji ve tıbbi cihaz müşterilerine biyofarmasötik ürün ve tıbbi cihaz geliştirme çözümleri sunmaktadır. Klinik araştırma birimleri, dış ortaklıklar, proje yönetimi, çalışma tasarımı ve izleme, biyoanalitik ve biyobelirteçler, farmakokinetik, modelleme ve simülasyon ve biyometri gibi klinik farmakoloji ve faz I ila IV klinik ve gerçek dünya kanıt çalışmaları, ruhsatlandırma işleri, protokol tasarımı, operasyonel planlama, çalışma ve saha başlatma, hasta alımı, proje yönetimi, kapsamlı saha ve tıbbi izleme, veri yönetimi ve biyoistatistik, farmakovijilans, tıbbi yazı ve mobil klinik hizmetleri dahil olmak üzere klinik geliştirme sunmaktadır. Şirket ayrıca ürün geliştirme ve düzenleme, pazara erişim ve sağlık ekonomisi ve sonuç araştırması ile RWE hizmetlerini içeren danışmanlık hizmetleri de sunmaktadır.
Fortrea Holdings Inc. Temel Bilgiler Özeti
| FTRE temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.14b |
| Kazançlar(TTM) | -US$986.20m |
| Gelir(TTM) | US$2.72b |
FTRE aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| FTRE gelir tablosu (TTM) | |
|---|---|
| Gelir | US$2.72b |
| Gelir Maliyeti | US$2.22b |
| Brüt Kâr | US$503.80m |
| Diğer Giderler | US$1.49b |
| Kazançlar | -US$986.20m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
May 05, 2026
| Hisse başına kazanç (EPS) | -10.55 |
| Brüt Marj | 18.50% |
| Net Kâr Marjı | -36.21% |
| Borç/Özkaynak Oranı | 187.0% |
FTRE uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/04 14:35 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Fortrea Holdings Inc. 13 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |